Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pfizer's biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018

pharmafileDecember 07, 2018

Tag: ASH , Rituxan , mabthera

PharmaSources Customer Service